Riskpilot← Back to searchSign inGet full accessZELLUNA IMMUNOTHERAPY AS
ASActiveOrg 816823862Ullernchausséen 64, 0379 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20169 employees
Revenue 2024
NOK 53K
-99% vs 2023
EBITDA margin
-199484.9%
-15% vs 2023
Equity ratio
71.5%
Financial strength
Net profit 2024
NOK -105,2M
-21% vs 2023
| Revenue | NOK 53K | -99% |
| EBITDA | NOK -105,7M | -15% |
| Net profit | NOK -105,2M | -21% |
| Total assets | NOK 50,4M | -64% |
| Equity | NOK 36M | -71% |
| Employees | 9 | — |
Legal name
ZELLUNA IMMUNOTHERAPY AS
Org number
816823862
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. mars 2016
Share capital
NOK 676 241
Employees
9 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Utvikle, markedsføre og selge medisinske produkter og utstyr samt det som står i forbindelse med dette.
Address
Ullernchausséen 64, 0379 Oslo
Email
post@zelluna.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 12 421 | 13 125 | 13 300 | 7 892 | 53 |
| Staff expenses | −19 831 | −0 | −0 | −0 | −0 |
| EBITDA | −33 314 | −33 964 | −50 844 | −92 203 | −105 727 |
| Depreciation & amort. | −254 | −695 | −1 309 | −1 866 | −3 845 |
| EBIT | −33 568 | −34 659 | −52 153 | −94 069 | −109 572 |
| Net financials | −696 | −659 | 3 081 | 7 262 | 4 410 |
| Profit before tax | −34 264 | −35 317 | −49 072 | −86 807 | −105 162 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −34 264 | −35 317 | −49 072 | −86 807 | −105 162 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 57 471 | 84 105 | 142 808 | 141 677 | 50 425 |
| Equity | 50 954 | 76 959 | 133 331 | 123 684 | 36 040 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 6 517 | 7 146 | 9 478 | 17 993 | 14 385 |
| Total debt | 6 517 | 7 146 | 9 478 | 17 993 | 14 385 |
EBITDA margin
-199484.9%
This company
15.8%
Market median
-1262663% vs market
20202024
Equity ratio
71.5%
This company
38.2%
Market median
+87% vs market
20202024
Return on equity
-291.8%
This company
18.4%
Market median
-1686% vs market
20202024
Net profit margin
-198418.9%
This company
8.1%
Market median
-2449716% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.40×
This company
0.62×
Market median
+35% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
NJ Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2025 | |
| Chairman | 2025 | |
| Former (5) | ||
| Chairman | 2022 – 2024 | |
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2020 – 2022 | |
| Chairman | 2024 – 2025 | |
| Board of Directors | 2022 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 15.13% | 15.13% | 2022 | |
| Company | 14.97% | 14.97% | 2024 | |
Geveran Trading Company Ltd | Company | 14.24% | 14.24% | 2023 |
Geveran Trading Company Ltd | Company | 14.09% | 14.09% | 2024 |
| Company | 13.08% | 13.08% | 2024 | |
| Company | 9.59% | 9.59% | 2024 | |
| Individual | 9.38% | 9.38% | 2022 | |
Merrill Lynch, Pierce, Fenner & Sm | Company | 8.37% | 8.37% | 2024 |
Ubs Switzerland Ag | Company | 4.59% | 4.59% | 2024 |
| Company | 4.31% | 4.31% | 2024 | |
| Company | 4.17% | 4.17% | 2024 | |
| Company | 3.42% | 3.42% | 2024 | |
Six Sis Ag | Company | 2.73% | 2.73% | 2024 |
J.P. Morgan Se | Company | 2.19% | 2.19% | 2024 |
| Individual | 2.05% | 2.05% | 2022 | |
| Company | 2.03% | 2.03% | 2024 | |
| Company | 1.96% | 1.96% | 2024 | |
| Company | 1.88% | 1.88% | 2024 | |
| Company | 1.73% | 1.73% | 2024 | |
St Catherine'S College In The | Company | 1.3% | 1.3% | 2024 |
| Company | 1.02% | 1.02% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ZELLUNA IMMUNOTHERAPY AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Namir Jafar Hassan | Chief Executive Officer | 0 companies |
| Hans Ivar Robinson | Chairman | 0 companies |
| Gustav Gaudernack | Board of Directors | 0 companies |
| Hans Peter Bøhn | Board of Directors | 0 companies |
| Hans Vassgård Eid | Board of Directors | 0 companies |
| Anders Tuv | Chairman | 0 companies |
| Bent Karsten Jakobsen | Chairman | 0 companies |
| Miles Stark Gerson | Board of Directors | 0 companies |